VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Exclusion Criteria

• •Previous treatment with VELCADE
• •Any experimental or anti-cancer therapy within 3 weeks before the first dose of study drug
• •Radiation therapy within 3 weeks before the first dose of study drug
• •Major surgery with 2 weeks before the first dose of study drug
• •Rituximab, Campath, or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug
• •Radioimmunotherapy or other toxin immunoconjugates such as Zevalin or Bexxar within 10 weeks before the first dose of study drug
• •History of allergic reactions to boron or mannitol compounds
• •Diagnosed or treated for another malignancy other than mantle cell lymphoma with 5 years before the first dose of study drug
• •Active systemic infection requiring treatment
• •Women patients must not be pregnant or breast-feeding, confirmed through pregnancy test obtained during screening (this test is not required for women who are post-menopausal or surgically sterile)
• •Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• •Concurrent treatment with another investigational drug or participation in non-treatment studies is not allowed if it interferes with participation in this clinical study